Opinion
Video
Author(s):
Panelists discuss how medical professionals consider PCSK9 inhibitors, bempedoic acid, and inclisiran in various clinical scenarios, their experiences with these newer therapies, the implications of the INCEPTION trial for treating patients with high-risk cardiovascular disease—particularly those who are statin-intolerant—the urgency of postcoronary event treatment, and emerging data on the broader impact of low-density lipoprotein cholesterol (LDL-C)–lowering therapies on quality of life.
Summary for Physicians: Challenges and Strategies for Nonstatin Lipid Therapies in Patients With Post-Cardiovascular Disease
Key Challenges in Implementing Nonstatin Therapies
Practical Solutions and Strategies
Treatment Selection Approach
Emerging Trends
Future Developments
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.